Antimicrobial resistance: A round table discussion on the “One Health” concept from the Gulf Cooperation Council Countries. Part One: A focus on Leadership

Alshamrani, Majid M.; Alhawsawi, Abdulelah; Al-Maani, Amal; Al-Abdely, Hail M.; Al-Katheeri, Huda; Al-Fadhli, Mariam; Alkhawaja, Safaa; Hawsawi, Abdulelah; Algwizani, Abdullah; Amri, Abdulrahman AL; Saedy, Abdulrahman AL; Omran, Abeer; Qunaibet, Ada; Othman, Adel; Rashidi, Afaf AL; Alhakawi, Ahmad; Harbi, Ahmed AL; El-Saed, Aiman; Alaa, Ali AL; Doweriej, Ali AL; Sharif, Ali Al; Somily, Ali M.; Al-Doweriej, Ali; Radidiah, Ali; Ruwaili, Alya AL; Gadalla, Azaheer; Binhelel, Bandar S.; Alshammari, Basim; Hussain, Ehab M.; Rabiah, Fahad AL; Bogoumi, Faisal AL; Saeed, Faroog; Anazi, Fatimah AL; Poff, Gregory; Abdely, Hail Mater Al; Roushdy, Hala; Albatshan, Hamad; Balkhy, Hanan H.; Hathout, H.; Bonnie, Henry Baffoe; Modaimegh, Hind AL; Zowawi, Hosam M.; Bukhari, Huda; Rashidi, Hussain AL; Jafali, Ibrahim AL; Qassem, Ibrahim; Tawfiq, Jaffar; Gramish, Jawaher; Al-Alawi, Maha M.; Aly, Mahmoud; Jeraisy, Majed Al; Alghoraibi, Majed; Alshamarani, Majid; Dalatony, Mervat Mohamed El; Ali, Mohamed Abdellatif; Quwazini, Mohamed Al; Abakhail, Mohammed; Essa, Mohammed Al; Shaalan, Mohamed; Balla, Munee; Enani, Musheera; Abuhasan, Muslim Younis; Attas, Nadia AL; Osman, Nahla; Al-Harbi, Naif O.; Mutairi, Noof AL; Fattoh, Nora; ALIbrahim, Raed; Hababi, Raed; Ibrahim, Raed; Shahrani, Saed Al; Jabbar, Saeed AL; Althawadi, Sahar; Aljohani, Sameera; Hajjar, Sami Al; Nazeer, Sayd; Jumaa, Suliman AL; Mahmoud, Suliman AL; Uzzaman, Taher; Oreibi, Talal AL; Sadig, Tarig; Desin, Taseen S.; Enazi, Thamer; Rabmo, Thuria; Nasser, Wafaa AL; Sultan, Zeinab Abbas; Qahtani, Abdullah AL; Shammrai, Abdullah AL; Otaibi, Abdulmalik AL; Shehri, Asma AL; Zahrani, Asma AL; Khazam, Bassem Abu; Suwayeh, Hani AL; Balani, Mansour AL; Rubaian, Meshal AL; Albelowi, Mohammed; Mutairi, Tareq AL; Dagunton, Nimfa; Mutlaq, Alaa; Mutairi, Diana AL; Otaibi, Hind AL; Rashoud, Isra AL; Aamar, Kholoud AL; Alsaqer, Taghreed A.; Srinivasan, Arjun; Aı̈dara-Kane, Awa; Allegranzi, Benedetta; Erlacher-Vindel, Elisabeth; Houfi, Ashraf El; Thomsen, Jens; Jamal, Khouloud; Jasim, Laila Mohamed; Alfaresi, Mubarak; Abdulrazzaq, Najiba; Omar, Zulfa; Al-Salman, Jameela; Khawajah, Safaa; Alkatheri, Huda; Ajmi, Jameela Al; Thani, Mohammed bin Hamad Al; Ishaq, Moza Al; Sharaf, Nahla

doi:10.1016/j.jiph.2018.05.007

Cited by 13 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This rate is similar to the cocolonization rate of 18.5% previously reported in Spanish hospitals in which bla OXA-48 is endemic [19]. It is likely due to several factors, including antimicrobial use in hospital and healthcare settings, infection control practices in various hospitals, and the use of antibiotics in the community [3,7]. S1) shows an overall statistically significant increase in carbapenem resistance gene detection (P ¼ 0.027; Fisher's exact test).…”

Section: Discussionsupporting

confidence: 83%

Molecular detection of carbapenem resistance genes in rectal swabs from patients in Gulf Cooperation Council hospitals

Al-Qahtani¹,

Tickler²,

Deesi

et al. 2021

Journal of Hospital Infection

View full text Add to dashboard Cite

Background: Gram-negative organisms harbouring carbapenem resistance genes (CRGs) are spreading globally, including in Gulf Cooperation Council (GCC) countries. However, relatively few data are available about carriage of CRGs in hospitalized patients in this region. Aim: To determine prevalence of CRG carriage and risk factors for colonization among patients in GCC hospitals. Methods: Rectal swabs were obtained from w50 intensive care unit (ICU) patients from each of 11 hospitals in five GCC countries between March and November 2019. The swabs were tested for the presence of bla KPC , bla NDM , bla VIM , bla IMP , and bla OXA-48 CRG using a commercial polymerase chain reaction test. Data on risk factors for colonization were collected and analysed. Findings: Of 529 specimens screened, 138 (26.1%) were positive for one or more CRGs. The positivity rates among the hospitals ranged from 8.0% to 67.3%; w20% of the positive specimens harboured 2 CRGs. The most common CRG detected was bla OXA-48 , which was present in 82 specimens (15.5%). Additional CRGs included bla NDM , bla VIM , bla KPC , and bla IMP either alone or in combination. Overall, 31.1% of patients on antibiotics on admission to the ICU were positive for CRGs compared to 16.5% not on antibiotic therapy (P <

show abstract

Section: Discussionsupporting

confidence: 83%

Molecular detection of carbapenem resistance genes in rectal swabs from patients in Gulf Cooperation Council hospitals

Al-Qahtani¹,

Tickler²,

Deesi

et al. 2021

Journal of Hospital Infection

View full text Add to dashboard Cite

show abstract

“…In addition, AMS should also involve collaboration with other sectors with the concept of the one health approach including the agriculture, animal husbandry and environmental use of antimicrobial agents. Some of the Arab countries have already initiated work in this area [ 27 ], however a regional approach is important particularly that meat products, fruits and vegetables from certain countries are sold in other countries and could serve as vehicles for transmission of resistant pathogens.…”

Section: Main Ams Interventions Obstacles and Proposed Solutionsmentioning

confidence: 99%

“…This center has created a strategic plan for improving AMR diagnosis and benchmarking. GCC countries have established national AMR surveillance plans in collaboration with the WHO[27]. In contrast, some of the Arab countries in North Africa and the Levant suffer from political instability and conflicts that have weakened their health infrastructures and displaced millions of people, hence hindering AMR surveillance[14,28,29].From the pre-COVID-19 era, AMR figures were alarming in the Arab world.…”

mentioning

confidence: 99%

Challenges to Antimicrobial Stewardship in the Countries of the Arab League: Concerns of Worsening Resistance during the COVID-19 Pandemic and Proposed Solutions

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic is expected to worsen the global problem of antimicrobial resistance (AMR). There is a heightened interest in understanding this effect and to develop antimicrobial stewardship (AMS) interventions accordingly to curb this threat. Our paper aims to evaluate the potential magnitude of COVID-19 on AMR and AMS with a focus on the countries of the Arab league, given the social, political, and economic environments. We also evaluate obstacles in applying the rational use of antibiotics, monitoring resistance trends in the midst of the pandemic, and evaluating the impact of the economic crisis in some countries. We aim to raise awareness about the potential effects of antibiotic overuse during the pandemic and to propose practical approaches to tackle this issue.

show abstract

“…Novel antimicrobials and new bacterial cell targets are urgently needed to overcome the everincreasing worldwide antimicrobial resistance (AMR), which is now widely accepted as a global health threat with leading causes of morbidity and mortality (Brown and Wright, 2016;Baptista et al, 2018). In May 2018, the World Health Organization (WHO), the Food and Agriculture Organization of the United Nations (FAO), and the World Organization for Animal Health (OIE) signed a Memorandum of Understanding (MoU) to support governments, health care workers, and stakeholders to engage and collaborate in the fight against AMR (Balkhy et al, 2018). Limiting the emergence of AMR is critical to preserve our ability to treat bacterial and microbial infections not only in humans, but also in animal, plant, food, and environment circumstances (Bhatia, 2018).…”

Section: Introductionmentioning

confidence: 99%

Topical Therapeutic Efficacy of Ebselen Against Multidrug-Resistant Staphylococcus aureus LT-1 Targeting Thioredoxin Reductase

et al. 2020

View full text Add to dashboard Cite

As a thiol-dependent enzyme, thioredoxin reductase (TrxR) is a promising antibacterial drug target. Ebselen, an organo-selenium with well-characterized toxicology and pharmacology, was recently reported to have potent antibacterial activity against Staphylococcus aureus. In this paper, we demonstrated that ebselen has strong bactericidal activity against multidrug-resistant (MDR) S. aureus based on taking TrxR as a major target and disruption of the redox microenvironment. Further, the topical therapeutic efficacy of ebselen for staphylococcal skin infections was assessed in a rat model. Treatment with ebselen significantly reduced the bacterial load and the expression of pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 beta (IL-1β) in S. aureus skin lesions; further, wound healing and pathological changes were obvious improved in ebselen-treated rats compare to controls. Finally, ebselen was found to sensitize S. aureus to curcumin, which may be due to their synergistic effects in inhibiting bacterial TrxR. Altogether, ebselen is an effective topical antibacterial agent in animal model of MDR S. aureus LT-1 skin infection. This may lay the foundation for further analysis and development of ebselen as an antibacterial agent for topical treatment of MDR staphylococcal infections.

show abstract

Antimicrobial resistance: A round table discussion on the “One Health” concept from the Gulf Cooperation Council Countries. Part One: A focus on Leadership

Cited by 13 publications

References 5 publications

Molecular detection of carbapenem resistance genes in rectal swabs from patients in Gulf Cooperation Council hospitals

Molecular detection of carbapenem resistance genes in rectal swabs from patients in Gulf Cooperation Council hospitals

Challenges to Antimicrobial Stewardship in the Countries of the Arab League: Concerns of Worsening Resistance during the COVID-19 Pandemic and Proposed Solutions

Topical Therapeutic Efficacy of Ebselen Against Multidrug-Resistant Staphylococcus aureus LT-1 Targeting Thioredoxin Reductase

Contact Info

Product

Resources

About